» Articles » PMID: 38007613

CRISPR-Cas9-generated PTCHD1 2489T>G Stem Cells Recapitulate Patient Phenotype when Undergoing Neural Induction

Overview
Journal HGG Adv
Specialty Genetics
Date 2023 Nov 26
PMID 38007613
Authors
Affiliations
Soon will be listed here.
Abstract

An estimated 3.5%-5.9% of the global population live with rare diseases, and approximately 80% of these diseases have a genetic cause. Rare genetic diseases are difficult to diagnose, with some affected individuals experiencing diagnostic delays of 5-30 years. Next-generation sequencing has improved clinical diagnostic rates to 33%-48%. In a majority of cases, novel variants potentially causing the disease are discovered. These variants require functional validation in specialist laboratories, resulting in a diagnostic delay. In the interim, the finding is classified as a genetic variant of uncertain significance (VUS) and the affected individual remains undiagnosed. A VUS (PTCHD1 c. 2489T>G) was identified in a child with autistic behavior, global developmental delay, and hypotonia. Loss of function mutations in PTCHD1 are associated with autism spectrum disorder and intellectual disability; however, the molecular function of PTCHD1 and its role in neurodevelopmental disease is unknown. Here, we apply CRISPR gene editing and induced pluripotent stem cell (iPSC) neural disease modeling to assess the variant. During differentiation from iPSCs to neural progenitors, we detect subtle but significant gene signatures in synaptic transmission and muscle contraction pathways. Our work supports the causal link between the genetic variant and the child's phenotype, providing evidence for the variant to be considered a pathogenic variant according to the American College of Medical Genetics and Genomics guidelines. In addition, our study provides molecular data on the role of PTCHD1 in the context of other neurodevelopmental disorders.

Citing Articles

Identifying SETBP1 haploinsufficiency molecular pathways to improve patient diagnosis using induced pluripotent stem cells and neural disease modelling.

Shaw N, Chen K, Farley K, Hedges M, Forbes C, Baynam G Mol Autism. 2024; 15(1):42.

PMID: 39350244 PMC: 11443744. DOI: 10.1186/s13229-024-00625-1.

References
1.
Torrico B, Fernandez-Castillo N, Hervas A, Mila M, Salgado M, Rueda I . Contribution of common and rare variants of the PTCHD1 gene to autism spectrum disorders and intellectual disability. Eur J Hum Genet. 2015; 23(12):1694-701. PMC: 4795195. DOI: 10.1038/ejhg.2015.37. View

2.
Schubert M, Thommandru B, Woodley J, Turk R, Yan S, Kurgan G . Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci Rep. 2021; 11(1):19482. PMC: 8484621. DOI: 10.1038/s41598-021-98965-y. View

3.
Chu V, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K . Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015; 33(5):543-8. DOI: 10.1038/nbt.3198. View

4.
Bliss T, Collingridge G . A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993; 361(6407):31-9. DOI: 10.1038/361031a0. View

5.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View